Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 514

PubMed for Gene (Select 2321)

1.

Elevated soluble VEGF receptor sFlt-1 correlates with endothelial injury in IgA nephropathy.

Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H.

PLoS One. 2014 Jul 9;9(7):e101779. doi: 10.1371/journal.pone.0101779. eCollection 2014.

2.

Prognostic significance of VEGFR1/Flt-1 immunoexpression in colorectal carcinoma.

Al-Maghrabi J, Gomaa W, Buhmeida A, Qari Y, Al-Qahtani M, Al-Ahwal M.

Tumour Biol. 2014 Sep;35(9):9045-51. doi: 10.1007/s13277-014-2124-5. Epub 2014 Jun 9.

PMID:
24908415
3.

Genetic variant in the 3'-untranslated region of VEGFR1 gene influences chronic obstructive pulmonary disease and lung cancer development in Chinese population.

Wang H, Yang L, Deng J, Wang B, Yang X, Yang R, Cheng M, Fang W, Qiu F, Zhang X, Ji W, Ran P, Zhou Y, Lu J.

Mutagenesis. 2014 Sep;29(5):311-7. doi: 10.1093/mutage/geu020. Epub 2014 Jun 2.

PMID:
24891316
4.

Soluble fms-like tyrosine kinase-1 in HIV infected pre-eclamptic South African Black women.

Govender N, Moodley J, Gathiram P, Naicker T.

Placenta. 2014 Aug;35(8):618-24. doi: 10.1016/j.placenta.2014.04.013. Epub 2014 May 14.

PMID:
24880209
5.

Expression of the sFLT1 gene in cord blood cells is associated to maternal arsenic exposure and decreased birth weight.

Remy S, Govarts E, Bruckers L, Paulussen M, Wens B, Hond ED, Nelen V, Baeyens W, van Larebeke N, Loots I, Sioen I, Schoeters G.

PLoS One. 2014 Mar 24;9(3):e92677. doi: 10.1371/journal.pone.0092677. eCollection 2014.

6.

Variability in mRNA expression of fms-like tyrosine kinase-1 variants in normal and preeclamptic placenta.

Surmon L, Bobek G, Makris A, Chiu CL, Lind CA, Lind JM, Hennessy A.

BMC Res Notes. 2014 Mar 17;7:154. doi: 10.1186/1756-0500-7-154.

7.

Synthesis of sFlt-1 by platelet-monocyte aggregates contributes to the pathogenesis of preeclampsia.

Major HD, Campbell RA, Silver RM, Branch DW, Weyrich AS.

Am J Obstet Gynecol. 2014 Jun;210(6):547.e1-7. doi: 10.1016/j.ajog.2014.01.024. Epub 2014 Jan 17.

8.

Vascular pool of releasable soluble VEGF receptor-1 (sFLT1) in women with previous preeclampsia and uncomplicated pregnancy.

Weissgerber TL, Rajakumar A, Myerski AC, Edmunds LR, Powers RW, Roberts JM, Gandley RE, Hubel CA.

J Clin Endocrinol Metab. 2014 Mar;99(3):978-87. doi: 10.1210/jc.2013-3277. Epub 2013 Dec 11.

9.

Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential.

d'Audigier C, Gautier B, Yon A, Alili JM, Guérin CL, Evrard SM, Godier A, Haviari S, Reille-Serroussi M, Huguenot F, Dizier B, Inguimbert N, Borgel D, Bièche I, Boisson-Vidal C, Roncal C, Carmeliet P, Vidal M, Gaussem P, Smadja DM.

Angiogenesis. 2014 Jul;17(3):603-16. doi: 10.1007/s10456-013-9413-2. Epub 2014 Jan 14.

PMID:
24419917
10.

Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.

Higashihara Y, Kato J, Nagahara A, Izumi K, Konishi M, Kodani T, Serizawa N, Osada T, Watanabe S.

Int J Oncol. 2014 Mar;44(3):662-8. doi: 10.3892/ijo.2013.2242. Epub 2013 Dec 31.

11.

Vascular endothelial growth factor receptor 1 expression in nasal polyp tissue.

Bobic S, Hox V, Callebaut I, Vinckier S, Jonckx B, Stassen JM, Jorissen M, Gevaert P, Carmeliet P, Bachert C, Ceuppens JL, Hellings PW.

Allergy. 2014 Feb;69(2):237-45. doi: 10.1111/all.12277. Epub 2013 Oct 15.

PMID:
24127643
12.

FLT1 kinase is a mediator of radioresistance and survival in head and neck squamous cell carcinoma.

Van Limbergen EJ, Zabrocki P, Porcu M, Hauben E, Cools J, Nuyts S.

Acta Oncol. 2014 May;53(5):637-45. doi: 10.3109/0284186X.2013.835493. Epub 2013 Sep 16.

PMID:
24041258
13.

Increased soluble Flt-1 correlates with delayed graft function and early loss of peritubular capillaries in the kidney graft.

Chapal M, Néel M, Le Borgne F, Meffray E, Carceles O, Hourmant M, Giral M, Foucher Y, Moreau A, Fakhouri F.

Transplantation. 2013 Oct 27;96(8):739-44. doi: 10.1097/TP.0b013e31829f4772.

PMID:
23912175
14.

Fcγ receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.

Justiniano SE, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda JM, Mo X, Cheney C, Hertlein E, Eubank TD, Marsh C, Muthusamy N, Butchar JP, Byrd JC, Tridandapani S.

J Biol Chem. 2013 Sep 13;288(37):26800-9. doi: 10.1074/jbc.M113.485185. Epub 2013 Jul 31.

15.

Evidence for angiogenesis-independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence.

Suspitsin EN, Kashyap A, Shelekhova KV, Sokolenko AP, Kuligina ESh, Iyevleva AG, Kornilov AV, Ehemann V, Yanus GA, Aleksakhina SN, Preobrazhenskaya EV, Zaitseva OA, Yatsuk OS, Klimashevsky VF, Togo AV, Imyanitov EN.

Med Oncol. 2013;30(3):644. doi: 10.1007/s12032-013-0644-2. Epub 2013 Jun 26.

PMID:
23801279
16.

Soluble Fms-like tyrosine kinase 1 is a novel predictor of brain natriuretic peptide elevation.

Kameda R, Yamaoka-Tojo M, Makino A, Wakaume K, Nemoto S, Kitasato L, Shimohama T, Tojo T, Machida Y, Izumi T.

Int Heart J. 2013;54(3):133-9.

17.

VEGFR1 and NRP1 endothelial expressions predict distant relapse after radical prostatectomy in clinically localized prostate cancer.

Talagas M, Uguen A, Garlantezec R, Fournier G, Doucet L, Gobin E, Marcorelles P, Volant A, DE Braekeleer M.

Anticancer Res. 2013 May;33(5):2065-75.

PMID:
23645757
18.

Genetic inhibition of vascular endothelial growth factor receptor-1 significantly inhibits the migration and proliferation of leukemia cells and increases their sensitivity to chemotherapy.

Xiu B, Zhang W, Huang B, Chen J, Lu H, Fu J, Xiong H, Liang A.

Oncol Rep. 2013 May;29(5):2030-8. doi: 10.3892/or.2013.2348. Epub 2013 Mar 13.

PMID:
23503608
19.

VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.

Beuselinck B, Karadimou A, Lambrechts D, Claes B, Wolter P, Couchy G, Berkers J, van Poppel H, Paridaens R, Schöffski P, Méjean A, Verkarre V, Lerut E, Joly F, Lebret T, Gravis G, Deplanque G, Descazeaud A, Leclercq NR, Molinié V, Patard JJ, Teghom C, Elaidi R, Zucman-Rossi J, Oudard S.

Acta Oncol. 2014 Jan;53(1):103-12. doi: 10.3109/0284186X.2013.770600. Epub 2013 Feb 20.

PMID:
23421954
20.

Structural investigation of the VEGF receptor interaction with a helical antagonist peptide.

Diana D, Di Stasi R, De Rosa L, Isernia C, D'Andrea LD, Fattorusso R.

J Pept Sci. 2013 Apr;19(4):214-9. doi: 10.1002/psc.2480. Epub 2013 Feb 19.

PMID:
23420665
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk